發(fā)布時間：2018-08-30 13:33

【摘要】：目的:系統(tǒng)評價ACEIs和ARBs對腎移植受者血紅蛋白濃度的影響。方法:計算機檢索Medline、EMBase、Cochrane CENTRAL、中國生物醫(yī)學數(shù)據(jù)庫(CBM)、相關期刊論文(CNKI)、中文科技期刊全文數(shù)據(jù)庫(VIP)和萬方數(shù)據(jù)庫,檢索截止至2016年7月,納入腎移植受者接受ACEIs或ARBs治療與安慰劑或空白對照的隨機對照試驗(RCTs),評價納入RCTs的偏倚風險,對同質性結果進行Meta分析,并評價結果的GRADE證據(jù)質量等級。結果:共納入10個RCTs,受試者1503例。Meta分析結果顯示隨訪3月、6月、12月及12月以上,ACEIs或ARBs組血紅蛋白濃度均低于安慰劑或空白對照組,MD、95%CI和P值分別為:SMD=-1.50,95%CI(-2.10,-0.90);SMD=-0.40,95%CI(-0.77,-0.02),P=0.04;SMD=-0.79,95%CI(-1.20,-0.38),P=0.000 1;SMD=-0.72,95%CI(-0.84,-0.60),P0.000 01。4個結果的GRADE證據(jù)質量等級分別為:中、低、低、中等質量。結論:基于當前證據(jù),RAS抑制劑可降低腎移植受者的血紅蛋白濃度。
[Abstract]:Objective: to evaluate the effect of ACEIs and ARBs on hemoglobin concentration in renal transplant recipients. Methods: Medline,EMBase,Cochrane CENTRAL, Chinese Biomedical Database (CBM), Chinese Journal Full-text Database (CNKI),) and Wanfang Database (VIP) were searched by computer. Randomized controlled trial (RCTs),) with ACEIs or ARBs therapy and placebo or blank control in renal transplant recipients included the risk of RCTs bias, Meta analysis of homogeneous results, and GRADE quality rating of the results. 緇撴灉:鍏辯撼鍏，

本文編號：2213227